Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Population pharmacokinetic—pharmacodynamic modeling of ketamine‐induced pain relief of chronic pain

Population pharmacokinetic—pharmacodynamic modeling of ketamine‐induced pain relief of chronic pain Aims: Pharmacological treatment of chronic (neuropathic) pain is often disappointing. In order to enhance our insight in the complex interaction between analgesic drug and chronic pain relief, we performed a pharmacokinetic—pharmacodynamic (PK—PD) modeling study on the effect of S(+)‐ketamine on pain scores in Complex Regional Pain Syndrome type 1 (CRPS‐1) patients. Methods: Sixty CRPS‐1 patients were randomly allocated to received a 100‐h infusion of S(+)‐ketamine or placebo. The drug infusion rate was slowly increased from 5 mg/h (per 70 kg) to 20 mg/h based upon the effect/side effect profile. Pain scores and drug blood samples were obtained during the treatment phase and pain scores were further obtained weekly for another 11 weeks. A population PK—PD model was developed to analyze the S(+)‐ketamine‐pain data. Results: Plasma concentrations of S(+)‐ketamine and its metabolite decreased rapidly upon the termination of S(+)‐ketamine infusion. The chance for an analgesic effect from ketamine and placebo treatment was 67±10% and 23±9% (population value±SE), respectively. The pain data were well described by the PK—PD model with parameters C50=10.5±4.8 ng/ml (95% ci 4.37–21.2 ng/ml) and t½ for onset/offset=10.9±4.0 days (5.3–20.5 days). Discussion: Long‐term S(+)‐ketamine treatment is effective in causing pain relief in CRPS‐1 patients with analgesia outlasting the treatment period by 50 days. These data suggest that ketamine initiated a cascade of events, including desensitization of excitatory receptor systems in the central nervous system, which persisted but slowly abated when ketamine molecules were no longer present. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Pain Wiley

Population pharmacokinetic—pharmacodynamic modeling of ketamine‐induced pain relief of chronic pain

Download PDF
10 pages

Loading next page...
 
/lp/wiley/population-pharmacokinetic-pharmacodynamic-modeling-of-ketamine-IJ1nBXxV2C

References (40)

Publisher
Wiley
Copyright
2011 European Federation of Chapters of the International Association for the Study of Pain
ISSN
1090-3801
eISSN
1532-2149
DOI
10.1016/j.ejpain.2010.06.016
pmid
20638877
Publisher site
See Article on Publisher Site

Abstract

Aims: Pharmacological treatment of chronic (neuropathic) pain is often disappointing. In order to enhance our insight in the complex interaction between analgesic drug and chronic pain relief, we performed a pharmacokinetic—pharmacodynamic (PK—PD) modeling study on the effect of S(+)‐ketamine on pain scores in Complex Regional Pain Syndrome type 1 (CRPS‐1) patients. Methods: Sixty CRPS‐1 patients were randomly allocated to received a 100‐h infusion of S(+)‐ketamine or placebo. The drug infusion rate was slowly increased from 5 mg/h (per 70 kg) to 20 mg/h based upon the effect/side effect profile. Pain scores and drug blood samples were obtained during the treatment phase and pain scores were further obtained weekly for another 11 weeks. A population PK—PD model was developed to analyze the S(+)‐ketamine‐pain data. Results: Plasma concentrations of S(+)‐ketamine and its metabolite decreased rapidly upon the termination of S(+)‐ketamine infusion. The chance for an analgesic effect from ketamine and placebo treatment was 67±10% and 23±9% (population value±SE), respectively. The pain data were well described by the PK—PD model with parameters C50=10.5±4.8 ng/ml (95% ci 4.37–21.2 ng/ml) and t½ for onset/offset=10.9±4.0 days (5.3–20.5 days). Discussion: Long‐term S(+)‐ketamine treatment is effective in causing pain relief in CRPS‐1 patients with analgesia outlasting the treatment period by 50 days. These data suggest that ketamine initiated a cascade of events, including desensitization of excitatory receptor systems in the central nervous system, which persisted but slowly abated when ketamine molecules were no longer present.

Journal

European Journal of Pain – Wiley

Published: Mar 1, 2011

There are no references for this article.